These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6998933)

  • 1. A randomized study of adjuvant immunotherapy with levamisole and Corynebacterium parvum in operable non-small cell lung cancer.
    Fox RM; Woods RL; Tattersall MH; Basten A
    Int J Radiat Oncol Biol Phys; 1980 Aug; 6(8):1043-5. PubMed ID: 6998933
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer.
    Woodruff M; Walbaum P
    Cancer Immunol Immunother; 1983; 16(2):114-6. PubMed ID: 6362846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
    Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
    Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies in cancer patients given Corynebacterium parvum/levamisole immunotherapy.
    Gatenby PA; Basten A; Tattersall MH; Fox RM
    Lancet; 1980 May; 1(8177):1082. PubMed ID: 6103412
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison of two nonspecific immune stimuli in antiblastic chemotherapy].
    Bianucci P; Pastorino G
    Arch Sci Med (Torino); 1980; 137(1):33-40. PubMed ID: 7458652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The growth and spontaneous dissemination of melanoma B16 and Lewis lung tumour in two sub-strains of C57BL/6J mice treated with Corynebacterium parvum and/or levamisole.
    Boeryd B; Benktson A
    Clin Exp Metastasis; 1983; 1(3):289-95. PubMed ID: 6546203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group.
    J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune adjuvant therapy in lung cancer.
    Holmes EC
    Prog Exp Tumor Res; 1980; 25():229-41. PubMed ID: 6986634
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
    Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
    Surg Forum; 1978; 29():155-7. PubMed ID: 401122
    [No Abstract]   [Full Text] [Related]  

  • 10. Design of phase-I trials of immunopotentiators for cancer therapy: levamisole and Corynebacterium parvum.
    Hirshaut Y; Pinsky CM; Wanebo HJ; Oettgen HF
    Ann N Y Acad Sci; 1976; 277(00):252-9. PubMed ID: 793480
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical trials of immunotherapy in lung cancer].
    Budzyński W; Orłowski TM
    Wiad Lek; 1984 Jul; 37(13):997-1003. PubMed ID: 6393588
    [No Abstract]   [Full Text] [Related]  

  • 12. [Active nonspecific immunotherapy combined with surgical treatment of lung carcinoma].
    Langer J
    Pneumonol Pol; 1980 Feb; 48(2):121-7. PubMed ID: 6988811
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current trends in immunotherapy of tumors of the lung].
    Crispano G; Toglia V; Tranchese D; Schettini R
    Arch Monaldi; 1983; 38(1-2):41-52. PubMed ID: 6675558
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant levamisole in the treatment of patients with resectable lung cancer.
    Amery WK
    Ann Clin Res; 1980; 12 Suppl 27():1-83. PubMed ID: 6999969
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant Corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx.
    Neifeld JP; Terz JJ; Kaplan AM; Lawrence W
    J Surg Oncol; 1985 Feb; 28(2):137-45. PubMed ID: 3881630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. The Ludwig Lung Cancer Study Group.
    Ludwig Lung Cancer Study Group
    Cancer Immunol Immunother; 1986; 23(1):1-4. PubMed ID: 2876772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of lung cancer. I. Review of clinical trials in non-small cell histologic types.
    Mikulski SM; McGuire WP; Louie AC; Chirigos MA; Muggia FM
    Cancer Treat Rev; 1979 Sep; 6(3):177-90. PubMed ID: 394836
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of the combination of Corynebacterium parvum and levamisole on murine tumors.
    Anaclerio A; Conti G; Moras ML; Barale C; Spreafico F
    Eur J Cancer (1965); 1977 Dec; 13(12):1451-53. PubMed ID: 413718
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
    Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of specific active immunotherapy in lung cancer.
    Souter RG; Gill PG; Gunning AJ; Morris PJ
    Br J Cancer; 1981 Oct; 44(4):496-501. PubMed ID: 7028069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.